论文部分内容阅读
与细菌耐药性迅速传播形成鲜明对比的是新抗生素开发的匮乏。本研究目的是对目前仍在沿用的传统抗生素进行评估。这些“老药”大都是一些非专利药,价格低廉,在以往应用中安全性良好,但目前在很多国家已无法或很难获得。此项调查在欧洲、美国、加拿大、澳大利亚等38个国家中的药剂师、微生物学专家、感染病专家中进行。所评估的抗菌药物由6名临床或微生物学专家组成的专家小组选出。不包括以下几类抗菌药物:(1)目前所有国家都能买到的抗
In stark contrast to the rapid spread of bacterial resistance, there is a scarcity of new antibiotics. The purpose of this study was to evaluate the traditional antibiotics that are still in use today. Most of these “old drugs” are generic drugs, which are inexpensive and safe to use in previous applications, but are currently unavailable or difficult to obtain in many countries. The survey was conducted in pharmacists, microbiologists and infectious disease experts in 38 countries including Europe, the United States, Canada and Australia. The antimicrobials evaluated were selected by a panel of six clinical or microbiological experts. Excludes the following types of antimicrobials: (1) Antibiotics that are currently available in all countries